IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 145 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Mr. Yujiro Hata est le President de IDEAYA Biosciences Inc, il a rejoint l'entreprise depuis 2015.
Quelle est la performance du prix de l'action IDYA ?
Le prix actuel de IDYA est de $28.01, il a diminué de 1.09% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de IDEAYA Biosciences Inc ?
IDEAYA Biosciences Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de IDEAYA Biosciences Inc ?
La capitalisation boursière actuelle de IDEAYA Biosciences Inc est de $2.4B
Est-ce que IDEAYA Biosciences Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 19 analystes ont établi des notations d'analystes pour IDEAYA Biosciences Inc, y compris 8 achat fort, 11 achat, 3 maintien, 0 vente et 8 vente forte
